andreu soldevila
CEO at Syna Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
Catalan, Spanish, French, English -
Topline Score
Bio
Experience
-
Syna Therapeutics
-
Spain
-
Biotechnology Research
-
1 - 100 Employee
-
CEO
-
Jan 2018 - Present
Development of Biosimilarswww.synatherapeutics.com Development of Biosimilarswww.synatherapeutics.com
-
-
-
Leanbio Pro
-
Spain
-
Biotechnology Research
-
1 - 100 Employee
-
Chairman and Founder
-
Apr 2014 - Present
-
-
CEO
-
Apr 2014 - Jan 2023
Lean Bioproduction concept in CMC for biotechnology and Biopharmaceutical products, Bioprocess development, Analytical development and manufacturing of New Biological entities and Biosimilars . www.leanbiopro,com
-
-
-
3p Biopharmaceuticals
-
Spain
-
Biotechnology Research
-
200 - 300 Employee
-
R&D Head of Department
-
Dec 2010 - Apr 2014
PEGylated Biosimilar, Monoclonal antibodies Biosimilars, Monoclonal Antibody drug conjugate(ADC), Human and veterinary Vaccines, Virus, New Biological entities and Bio-based molecules synthesisParticipating in laboratory design, equipment acquisition and building Process development team.Areas of expertise: Biosimilars, Cell line development, Process and Analytical development.Business development, Project management and Technology Transfer PEGylated Biosimilar, Monoclonal antibodies Biosimilars, Monoclonal Antibody drug conjugate(ADC), Human and veterinary Vaccines, Virus, New Biological entities and Bio-based molecules synthesisParticipating in laboratory design, equipment acquisition and building Process development team.Areas of expertise: Biosimilars, Cell line development, Process and Analytical development.Business development, Project management and Technology Transfer
-
-
-
IPSEN PHARMA
-
France
-
Retail Office Equipment
-
Protein Bio-Analysis Head of department
-
2008 - 2010
Developed a Bioanalysis platform for the characterization and quantitation of Biotherapeutics for Tox and PK-PD studies in the preclinical and clinical trials.Long-term release formulation, stability studies, Bioanalysis, Mass spectrometry and Immunology methods, High throughput analysis Developed a Bioanalysis platform for the characterization and quantitation of Biotherapeutics for Tox and PK-PD studies in the preclinical and clinical trials.Long-term release formulation, stability studies, Bioanalysis, Mass spectrometry and Immunology methods, High throughput analysis
-
-
-
Inkemia
-
United States
-
Research Services
-
Coordinator of the Biotechnology department
-
1999 - 2008
Research and development of small molecules by means of biocatalysis, biotransformation and biosynthesis strategiesMicrobiology tests in the GLP development of new moleculesMicrobiology test validation of the pharmaceutical pilot plant Teaching of Microbiology and Biotechnology in different MsC Research and development of small molecules by means of biocatalysis, biotransformation and biosynthesis strategiesMicrobiology tests in the GLP development of new moleculesMicrobiology test validation of the pharmaceutical pilot plant Teaching of Microbiology and Biotechnology in different MsC
-
-
Education
-
Universitat Autònoma de Barcelona
PhD, Biotechnology -
UVIC
"BS", Biotechnology -
manel blancafort
-
manel blancafort
-
manel blancafort